Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
1998). To identify MG, we labeled sections for Sox2 or Sox9. Antibodies to Sox2 and Sox9 are known to label the nuclei or MG in the INL and the nuclei of astrocytes at the vitread surface of the ...